Drug
Enlicitide Decanoate
Enlicitide Decanoate: highest development phase Approved, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| LIPFENDRA | Approved | |
| Enlicitide Decanoate NCT07058077 | Phase 2/3 | Heterozygous Familial Hypercholesterolemia (HeFH) |
Latest
No recent events.
Follow Enlicitide Decanoate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.